Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bortezomib · Velcade, LDP-341

Small molecule · Inhibitor of 26S proteasome · developed by Takeda Pharms Usa

Approved FDA, May 2003
1 Registered trials

What is Bortezomib?

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome, the protein complex that degrades ubiquitinated proteins. Blocking this degradation disrupts cell homeostasis and can lead to cancer cell death. It is studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Velcade, LDP-341, NSC-681239, PS-341
Drug type
Small molecule
Targets
26S proteasome
Mechanism
Inhibitor of 26S proteasome
Pathways
ubiquitin-proteasome pathway, protein homeostasis
Therapy area
Oncology
Developer
Takeda Pharms Usa
In trials of
PFE
FDA status
Approved as Velcade (May 13, 2003), NDA021602 · FDA label
UNII
69G8BD63PP

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 28, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06152575 Phase 3 Multiple Myeloma Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.